Vontobel Holding Ltd. Lowers Stock Holdings in Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

Vontobel Holding Ltd. reduced its position in shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) by 49.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 152,100 shares of the biopharmaceutical company’s stock after selling 147,900 shares during the period. Vontobel Holding Ltd. owned about 0.07% of Sangamo Therapeutics worth $155,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Meritage Portfolio Management boosted its position in shares of Sangamo Therapeutics by 8.6% during the third quarter. Meritage Portfolio Management now owns 85,000 shares of the biopharmaceutical company’s stock worth $74,000 after buying an additional 6,740 shares during the period. Shelton Wealth Management LLC purchased a new position in shares of Sangamo Therapeutics during the fourth quarter worth $29,000. Wealth Enhancement Advisory Services LLC boosted its position in shares of Sangamo Therapeutics by 55.4% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 108,945 shares of the biopharmaceutical company’s stock worth $94,000 after buying an additional 38,850 shares during the period. Charles Schwab Investment Management Inc. boosted its position in shares of Sangamo Therapeutics by 5.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,103,326 shares of the biopharmaceutical company’s stock worth $956,000 after buying an additional 57,125 shares during the period. Finally, Sageworth Trust Co purchased a new position in shares of Sangamo Therapeutics during the fourth quarter worth $61,000. 56.93% of the stock is currently owned by hedge funds and other institutional investors.

Sangamo Therapeutics Price Performance

Sangamo Therapeutics stock opened at $1.07 on Friday. Sangamo Therapeutics, Inc. has a 1-year low of $0.30 and a 1-year high of $3.18. The stock has a market cap of $223.26 million, a PE ratio of -1.43 and a beta of 1.30. The stock’s fifty day moving average is $1.45 and its two-hundred day moving average is $1.39.

Analyst Ratings Changes

SGMO has been the subject of several research analyst reports. Wells Fargo & Company lowered their price target on Sangamo Therapeutics from $3.00 to $2.00 and set an “equal weight” rating for the company in a research report on Tuesday, December 31st. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Sangamo Therapeutics in a report on Monday, January 27th. StockNews.com lowered Sangamo Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, December 24th. Truist Financial decreased their target price on Sangamo Therapeutics from $7.00 to $5.00 and set a “buy” rating for the company in a report on Thursday, January 23rd. Finally, Jefferies Financial Group decreased their target price on Sangamo Therapeutics from $7.00 to $3.00 and set a “buy” rating for the company in a report on Tuesday, December 31st. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, Sangamo Therapeutics has an average rating of “Moderate Buy” and an average target price of $5.17.

Sangamo Therapeutics Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.